Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

Introduction Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine the presence...

RR Mathiesen，E Borgen，A Renolen，... - 《Breast Cancer Research》

Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story

Prediction is very difficult, especially about the future. 鈥擭iels Bohr There are three evolving stories that have the potential to improve outcomes for patients with localized triple-negative breast cancer (TNBC), a phenotypically defi...

Sparano，A J. - 《Journal of Clinical Oncology》

The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer

Abnormalities of chromosome 17 are important molecular genetic events in human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor suppre...

W Zhang，Y Yu - 《International Journal of Molecular Sciences》

IJMS, Vol. 12, Pages 5672-5683: The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer

Abnormalities of chromosome 17 are important molecular genetic events in human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor suppressor genes (p53, BRCA1 and HIC-1) or DNA double-strand break repair gene (RDM1) ar...

Zhang，Wei，Yu，...

The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer.

Abnormalities of chromosome 17 are important molecular genetic events in human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor suppre...

Zhang，Wei，Yingyan - 《International Journal of Molecular Sciences》

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy

Mammary gland morphology and physiology are supported by an underlying cellular differentiation hierarchy. Molecular features associated with particular ce...

AD Pfefferle，BT Spike，GM Wahl，... - 《Breast Cancer Research & Treatment》

Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)

Background: mTOR inhibitors can activate p73, a pro-apoptotic member of the p53 family, and enhance the sensitivity of breast cancer cells to cisplatin and paclitaxel. Thus, we hypothesized that combined use of the mTOR inhibitor everoli...

IA Mayer，B Jovanovic，VG Abramson，... - 《Cancer Research》

Optimal adjuvant cytotoxic therapy for breast cancer

The optimal adjuvant chemotherapy regimen for breast cancer may be changing in light of recent evidence. Classic cyclophosphamide, methotrexate, and 5-fluo...

C Lohrisch，AD Leo，MJ Piccart - 《Breast》